The mutational landscape of cold agglutinin disease: CARD11 and CXCR4 mutations are correlated with lower hemoglobin levels
Sign Up to like & getrecommendations! Published in 2021 at "American Journal of Hematology"
DOI: 10.1002/ajh.26205
Abstract: AUTHOR CONTRIBUTIONS Musa Yilmaz, Hagop Kantarjian, Naval Daver, Farhad Ravandi designed the study, analyzed the data, and wrote the paper. Musa Yilmaz, Sherry Pierce, Naval Daver, collected and analyzed the data. Sanam Loghavi, Keyur Patel,… read more here.
Keywords: mutational landscape; disease card11; cold agglutinin; agglutinin disease ... See more keywords
Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease.
Sign Up to like & getrecommendations! Published in 2023 at "American journal of hematology"
DOI: 10.1002/ajh.26965
Abstract: Cold agglutinin disease (CAD) is a rare, autoimmune, classical complement pathway (CP)-mediated hemolytic anemia. Sutimlimab selectively inhibits C1s of the C1 complex, preventing CP activation while leaving the alternative and lectin pathways intact. In Part… read more here.
Keywords: complement; agglutinin disease; sutimlimab; treatment ... See more keywords
Multifocal thrombosis with peripheral gangrene in a young boy: Mycoplasma infection triggered cold agglutinin disease.
Sign Up to like & getrecommendations! Published in 2021 at "Immunobiology"
DOI: 10.1016/j.imbio.2021.152075
Abstract: Cold agglutinin disease (CAD) is extremely rare in children. We report an 8-year-old boy who presented with gangrene of right foot with hypertension and absent lower limb pulses. Blood peripheral smear evidence of autoagglutination and… read more here.
Keywords: cad; cold agglutinin; agglutinin; peripheral gangrene ... See more keywords
Healthcare resource utilization among patients with cold agglutinin disease in Denmark
Sign Up to like & getrecommendations! Published in 2021 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2021.1960494
Abstract: Abstract Objectives Cold agglutinin disease (CAD) is a rare form of autoimmune hemolytic anemia that may manifest in complement-mediated chronic hemolytic anemia, profound fatigue, and transient agglutination-mediated circulatory symptoms. This study compared the healthcare resource… read more here.
Keywords: healthcare resource; among patients; patients cad; cold agglutinin ... See more keywords
Monoclonal antibodies for treatment of cold agglutinin disease
Sign Up to like & getrecommendations! Published in 2023 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2023.2209265
Abstract: ABSTRACT Introduction Cold agglutinin disease (CAD) is a difficult-to-treat autoimmune hemolytic anemia and B cell lymphoproliferative disorder associated with fatigue, acrocyanosis, and a risk of thromboembolic events. Cold-induced binding of autoantibody agglutinates red blood cells… read more here.
Keywords: agglutinin disease; complement; antibody based; treatment ... See more keywords
Complement-directed therapy for cold agglutinin disease: sutimlimab.
Sign Up to like & getrecommendations! Published in 2023 at "Expert review of hematology"
DOI: 10.1080/17474086.2023.2218611
Abstract: INTRODUCTION Cold agglutinin disease (CAD) is a rare subtype of autoimmune hemolytic anemia defined as a distinct, low-grade lymphoproliferative disorder and characterized by the presence of immunoglobulin M (IgM) antibodies that recognize the "I" antigen… read more here.
Keywords: cad; agglutinin disease; complement; sutimlimab ... See more keywords
Sustained sutimlimab response for 3 years in patients with cold agglutinin disease: A phase I, open‐label, extension trial
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18289
Abstract: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia (AIHA), which leads to fatigue and acrocyanosis.1– 4 Until recently, treatment of CAD was mainly based on reduction of the Bcell clone by rituximab or… read more here.
Keywords: sustained sutimlimab; sutimlimab response; agglutinin disease; trial ... See more keywords
Heavy chain/light chain assay is a useful biomarker for diagnosis and management of patients with cold agglutinin disease
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18317
Abstract: before treatment, which can lead to lower detection by HLC. However, this study confirms that HLC is a useful biomarker to detect and to follow the monoclonal component in either primary or secondary agglutinin disease. read more here.
Keywords: agglutinin disease; heavy chain; useful biomarker; chain ... See more keywords
Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13903
Abstract: Cold agglutinin disease (CAD) is a rare chronic autoimmune haemolytic anaemia, driven mainly by classical complement pathway activation, leading to profound fatigue and poor quality of life. In the Phase 3 CADENZA trial, sutimlimab—a C1s… read more here.
Keywords: patient reported; agglutinin disease; placebo; fatigue ... See more keywords
Development of the Cold Agglutinin Disease Symptoms and Impact Questionnaire (CAD-SIQ).
Sign Up to like & getrecommendations! Published in 2023 at "European journal of haematology"
DOI: 10.1111/ejh.13984
Abstract: OBJECTIVES Cold agglutinin disease (CAD) is a rare autoimmune hemolytic anemia. This study aimed to identify disease-related symptoms and impacts important to patients with CAD, and to develop a novel CAD-specific patient-reported outcome measure. METHODS… read more here.
Keywords: cad; agglutinin disease; disease; impact questionnaire ... See more keywords
How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?
Sign Up to like & getrecommendations! Published in 2022 at "Transfusion"
DOI: 10.1111/trf.17038
Abstract: High titers of cold agglutinins jeopardize the quality of an apheresis product meant for autologous or allogeneic transplant. Management of transplant patients with cold agglutinin disease (CAD) is often experience‐based and under reported, yet decisions… read more here.
Keywords: cell; agglutinin disease; warm hpc; viability ... See more keywords